

Remarks

Claim 1 has been amended by incorporating the values for R<sub>2</sub> of formulae (F') and (H') from dependent Claim 11. The claim now reads on all of the values for R<sub>2</sub> recited in claim 11.

Claim 2 has been amended to introduce the definition of R<sub>2</sub> from Claim 1 prior to the amendment to add the values of formulae (F') and (H'). It has also been amended to conform the list of possible substituents on a cyclohexyl group with that given in the description at page 8, lines 19 to 20. Claim 2 is believed to be entitled to the first priority date.

Claim 9 has been amended to incorporate the definitions (ix), (x) and (xi) of R<sub>2</sub> from Claim 10. As previously written, the definition of R<sub>2</sub> in Claim 1 did not read on the values given in definitions (ix), (x) and (xi) in Claim 9.

Claim 10 has been amended to remove certain values for R<sub>2</sub> when it represents a substituted phenyl group. These values fall outside the scope of the definition of R<sub>2</sub> in Claim 1. Certain typographical errors have also been corrected.

Corresponding amendments have been made in the specification.

In addition, the description has been amended to correct certain clerical errors.

Applicants would also like to take this opportunity to draw the Examiner's attention to a divisional application that they have filed off the parent of the present application.

The parent of the present application was voluntarily limited to a single species, after a restriction requirement had been made. Applicants are unsure as to whether the restriction requirement continues to apply. They have filed the present continuation application, and a divisional application, which is pending as serial number 10/803,157. If the restriction requirement continues to apply, Applicants plan to limit the claims in this continuation application to the invention identified as Group VIII in the restriction requirement in the parent. The claims in the divisional application would then be directed to the subject matter not claimed in the parent or continuation. However, Applicants would first need clarification from the Examiner on whether Group VIII in the restriction requirement in the parent included all monocyclic carbocyclic Cy groups, or just phenyl groups.

An updated listing of co-pending applications and patents is provided on the next page.

Finally, Applicants have noticed that their previous amendment did not contain underlining to show text that had been inserted. This was due to a printer problem. A freshly printed copy of the previous amendment is attached, showing the underlining.

Serial No. 10/754,923  
Supplemental Preliminary Amendment

**Co-Pending Lilly and Tularik Applications and Patents**

**Co-pending applications - Assigned to Eli Lilly and Company**

- 09/926,712** (national stage of WO 00/76971)
- 09/926,716** (national stage of WO 00/76970 - abandoned)
- 10/030,188** (national stage of WO 01/96303)
- 10/030,186** (national stage of WO 01/96304)
- 10/030,189** (national stage of WO 01/96296)
- 10/477,192** (national stage of WO 02/100847)
- 10/486,138** (national stage of WO 03/084929)
- 10/803,187** (divisional of 10/030,187, the parent of the present application)

**Co-pending applications and patents - Assigned to Tularik Limited**

- US 6262069** and **US 6420438** (national stage of WO 99/11657 and continuation)
- 09/988,082** (continuation-in-part of 09/485,678, WO 99/11658 and of WO 00/77027)
- 10/148,174** (national stage of WO 01/44226)
- 10/296,245** (national stage of WO 01/96305)
- 10/432,365** (national stage of WO 02/47762)

Serial No. 10/754,923  
Supplemental Preliminary Amendment

**COMMUNICATION BY TELEPHONE**

The undersigned's office is located in the United Kingdom, and hence the Examiner may have difficulty contacting him from the USPTO by telephone. If the Examiner wishes to speak with the undersigned by telephone, he can contact the undersigned by e-mail at [martinahay@martin-a-hay.com](mailto:martinahay@martin-a-hay.com), or leave a message with Linda McDonald at (317) 433 7140 (Eli Lilly and Company).

**CONCLUSION**

Applicants believe that the amendments they have made have placed the application in order for allowance.

Favorable consideration of the application is requested.

Respectfully submitted,

*Mart A Hay*

Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

Email: [martinahay@martin-a-hay.com](mailto:martinahay@martin-a-hay.com)

Customer No. 24330  
[Martin A. Hay & Co.,  
13 Queen Victoria Street  
Macclesfield  
Cheshire  
SK11 6LP  
UNITED KINGDOM]

April 28, 2004